(HIMS) Hims & Hers Health, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(HIMS) Hims & Hers Health, Inc. Complete Analysis Pack
See the Bigger Picture
This Hims & Hers Health, Inc. BCG Matrix helps you see how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, research, and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
GLP-1 weight loss
GLP-1 weight loss is Hims & Hers Health, Inc.'s clearest Star: obesity care is a fast-growing market, and the company sells it through recurring telehealth and prescription fulfillment. In 2025, management kept expanding access while defending supply, which supports scale and repeat use. It needs heavy marketing and inventory support, but that is exactly what a Star demands.
Mental health subscriptions
Mental health subscriptions fit "Stars": Hims & Hers served 2.2 million subscribers in FY2024 and revenue rose 69% to $1.48 billion, showing strong demand. Mental health is still a large digital-care category with low penetration, and repeat visits plus ongoing medication management can lift lifetime value. With more investment, this line can keep scaling fast as adoption deepens.
Primary care visits
Primary care visits are a strong entry point for Hims & Hers Health, Inc., because they bring users into the platform early and can lift repeat use across prescriptions, labs, and follow-up care. That matters in a category still moving online: Hims & Hers guided 2025 revenue to about $2.3 billion after 2024 revenue of $1.48 billion, showing scale and growth. In BCG terms, this fits a Star: high-growth demand with room to deepen wallet share.
Women’s health rollout
Women’s health is a clear Stars segment for Hims & Hers: the Hers platform widens the audience beyond the male core and supports more repeat use through hormonal care, sexual health, and wellness. By FY2025, the company was still scaling at strong double-digit revenue growth, so this category can justify heavy spend on brand, paid media, and retention. Recurring care makes the lifetime value story stronger.
- Broadens the customer base beyond men
- Drives repeat prescriptions and visits
- Supports higher brand and channel spend
International expansion
International expansion is a Star for Hims & Hers Health, Inc. because the long-term addressable market is much bigger than its U.S.-heavy base, which produced about $1.48 billion of revenue in 2024. Early non-U.S. penetration is still low, so today’s share is small, but that also leaves room for outsized growth if execution stays tight.
The 2024 ZAVA deal gave Hims & Hers a real foothold in the UK and parts of Europe, but overseas sales still trail the U.S. by a wide margin. That means this is not yet a cash engine, but it is a high-upside growth lane with room to scale.
- Large global demand base
- Low current international share
- Strong upside if execution holds
Hims & Hers’ Fastest-Growing Stars Are Driving the Next Growth Wave
Stars for Hims & Hers Health, Inc. are the fastest-growing, recurring-care lines: GLP-1 obesity, mental health, primary care, and women’s health. FY2024 revenue was $1.48 billion, and management guided FY2025 revenue to about $2.3 billion, showing scale plus demand. These segments need heavy spend, but they can keep compounding through repeat prescriptions and visits.
| Star area | FY2024/FY2025 data | Why it fits |
|---|---|---|
| GLP-1 | Key growth driver | Fast-growing market |
| Mental health | 2.2M subscribers | Recurring use |
| Company | $1.48B to ~$2.3B | Strong growth |
What is included in the product
Detailed Word Document
Hims & Hers’ BCG matrix maps telehealth stars, cash-generating subscriptions, growth question marks, and low-share dogs.
Editable Excel File
Quick BCG view to spot Hims & Hers’ cash cows, stars, and drag, so teams can fix growth pain fast.
Reference Sources
Provides a credible source trail for Hims & Hers Health, Inc. that supports faster due diligence and more confident decisions.
Cash Cows
Sildenafil and tadalafil
Sildenafil and tadalafil fit Hims & Hers Health, Inc. as a cash cow: ED is a mature, repeat-use category with low churn and known customer acquisition, while Hims & Hers ended 2024 with about 2.2 million subscribers and $1.5 billion in revenue. That scale lets the brand harvest steady cash from a well-known 30-day refill model with modest extra investment.
Finasteride hair-loss Rx
Finasteride hair-loss Rx is one of Hims & Hers Health, Inc.'s most established recurring offers, built on a 1 mg daily dose and long-term use. Because patients often stay on therapy for months or years, it supports steady subscription cash flow. This makes it a cash cow: less about fast growth, more about monetizing an installed base. The business also benefits from low re-acquisition costs versus newer categories.
Minoxidil maintenance
Minoxidil maintenance is a low-complexity, repeat-fill hair-loss use case, so it behaves like a cash cow inside Hims & Hers Health, Inc.'s platform. Hair loss is a familiar problem, which supports steady reorders and low servicing cost. That matters at scale: Hims & Hers reported about $1.5 billion in FY2024 revenue and over 2 million subscribers, giving this category a strong margin base.
Skincare subscriptions
Skincare subscriptions fit Hims & Hers Health, Inc.’s Cash Cow role because moisturizers, serums, and cleansers are familiar, repeatable, and easy to reorder. The subscription model keeps demand steady, so the line can keep generating cash without heavy product reinvention.
It also scales better than newer care categories, since the same routine products can be sold to a wider base with low added complexity. That makes skincare a useful profit pool while Hims & Hers Health, Inc. keeps investing in faster-growing offers.
- Repeat buys support stable cash flow.
- Simple products lower selling friction.
- Low reinvention need keeps costs down.
Wellness supplements
Wellness supplements fit Cash Cows because vitamins and supplements are a stable add-on, easy to bundle into recurring orders, and they lift basket size. In Hims & Hers Health, Inc.'s 2025 mix, this kind of repeat, low-friction SKU can support cash conversion even if growth trails newer care lines.
- Stable add-on demand
- Boosts recurring order value
- Slower growth, solid cash flow
Hims’ Cash Cows: Repeat-Use Prescriptions Drive $1.5B
Sildenafil,tadalafil,finasteride,minoxidil,and skincare stay Hims & Hers Health,Inc.'s cash cows: mature,repeat-use offers with low churn and low re-acquisition cost. FY2024 revenue was about $1.5B and subscribers topped 2.2M, so these lines keep producing cash more than growth.
| Cash cow | Why | 2024 scale |
|---|---|---|
| ED,hair loss,skincare | Repeat fills,steady demand | $1.5B;2.2M subs |
Get Your Copy
Hims & Hers Health, Inc. Reference Sources
You’re previewing the exact Hims & Hers Health, Inc. BCG Matrix document you’ll receive after purchase. What you see here is the final, fully formatted file—no demo pages or hidden changes. Once purchased, it’s ready to download, edit, print, or share right away.
Dogs
Wholesale partnerships
Wholesale partnerships sit outside Hims & Hers Health, Inc.’s core direct-to-consumer subscription model, so they usually score as a Dog in the BCG Matrix. They cut control over pricing, customer data, and auto-renew billing, which weakens lifetime value versus the company’s $1.48 billion 2024 revenue engine built on direct recurring sales. That makes wholesale a low-fit, low-leverage channel.
One-time OTC devices
One-time OTC devices fit Hims & Hers Health, Inc. as a Dogs asset in a BCG view: they bring one sale, not a repeat bill, so lifetime value stays below subscription plans. They also need more inventory and working capital, which hurts capital use when the model is built on recurring care. In 2025, the company’s growth remained subscription-led, so low-repeat OTC devices look like a lower-priority use of cash.
Commodity cosmetics
Commodity cosmetics sit in the Dogs bucket because they are easy to copy, widely available, and highly price sensitive. Hims & Hers Health, Inc. can’t defend these SKUs with brand alone, so share and growth stay modest versus higher-margin wellness and prescription lines. In a market with thousands of near-identical products, even strong digital reach does not create a moat.
Low-frequency accessories
Low-frequency accessories fit Hims & Hers Health, Inc. as Dogs in the BCG matrix: they are bought rarely, create little repeat demand, and do not meaningfully raise retention. The core business is still recurring digital care, while accessories stay a small add-on with limited strategic pull.
- Rare purchases, weak repeat demand
- Little retention lift
- Effort can exceed payoff
- Priority stays on recurring care
Non-core retail add-ons
Non-core retail add-ons are classic Dogs: low-share, low-growth items that add catalog clutter but very little profit or moat. Hims & Hers Health, Inc. is still driven by its subscription model; the core business generated about $1.48 billion in 2024 revenue, so small add-ons are unlikely to move the needle.
- Low growth, low strategic value
- Weak moat-building impact
- Can distract from core subscriptions
These items may help basket size a bit, but they do not scale like recurring care plans. In BCG terms, they fit the Dogs quadrant because share is small and growth contribution is limited.
Hims & Hers’ Low-Value “Dog” Products Drag on Retention
Dogs at Hims & Hers Health, Inc. are low-repeat, low-control items like wholesale, OTC devices, cosmetics, and accessories. They do little for retention or pricing power, while the core model still centered on about $1.48 billion revenue in 2024 from recurring direct-to-consumer subscriptions.
| Dog item | Why it fits |
|---|---|
| Wholesale | Low control, weak data, low LTV |
| OTC devices | One-time sale, no repeat billing |
| Cosmetics | Easy to copy, price sensitive |
| Accessories | Rare buys, little retention lift |
Question Marks
Menopause and HRT
Menopause and HRT is a Question Mark for Hims & Hers Health, Inc.: the addressable women’s-health market is large, with about 6,000 U.S. women reaching menopause each day, but digital penetration is still early. That leaves Hims & Hers with limited share today, even as demand for access and convenience rises. It needs continued investment in product, care delivery, and marketing to see if it can scale into a leader.
Fertility care
Fertility care fits the Question Mark bucket: demand is real, with 432,641 U.S. ART cycles reported by the CDC in 2022, and patients often pay out of pocket. Still, digital fertility is a small slice of a large market, so Hims & Hers Health, Inc. has an attractive growth path but limited proof at scale. If conversion and retention hold, it can move toward a Star.
Lab testing diagnostics
Lab testing diagnostics is still a Question Mark for Hims & Hers Health, Inc.: it can lift medical utility and retention, but adoption is still early. The category only becomes strategic if it turns one-off tests into repeat use, since that feeds recurring care. In 2025, the real test is conversion, not scale.
Chronic disease management
Chronic disease management is a Question Mark for Hims & Hers Health, Inc.: metabolic health demand is rising fast, with the World Health Organization saying 1 in 8 adults had obesity in 2022, but the company still needs proof it can win beyond core telehealth categories. If it scales trusted care, this could turn into a Star; if not, capital should be reallocated.
- High growth, weak share
- Credibility still being built
- Invest or walk away
B2B employer care
B2B employer care gives Hims & Hers Health, Inc. a much larger route to users, but it is still a small part of the business. With 2.4 million subscribers and $1.48 billion in 2024 revenue, employer-led care is not yet the main engine, so this fits a Question Mark: big upside, low share.
Large channel, low current share
Strong growth option, high execution risk
Needs proof on repeat demand
Hims & Hers' Big Bets Need Proof
Question Marks in Hims & Hers Health, Inc. are early-stage growth bets: menopause, fertility, lab testing, chronic disease, and employer care all have big markets but still low share. Hims & Hers Health, Inc. had 2.4 million subscribers and $1.48 billion revenue in 2024, but these lines need proof of repeat use and scale.
| Area | Signal | Status |
|---|---|---|
| Women’s health | Large demand | Question Mark |
| Fertility | 432,641 ART cycles | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.